• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Lalan Wilfong on Texas Oncology's Experience With the OCM

Video

The Oncology Care Model (OCM) has been challenging for Texas Oncology as it has for all practices, said Lalan Wilfong, MD, executive vice president of Quality Programs at Texas Oncology.

The OCM has been challenging for Texas Oncology as it has for all practices, said Lalan Wilfong, MD, executive vice president of Quality Programs at Texas Oncology.

Transcript

What has Texas Oncology’s experience with the Oncology Care Model been like thus far?

[OCM] has been challenging for Texas Oncology as it has for all practices. But it did stop and make us think about how to take care of patients and being more patient-centric than we ever have been before.

A lot of good has come out of the program for us. Things about having shared-decision making with patients, really thinking about the cost of care, having access for our patients in our clinics to avoid hospitalization’s and [emergency departments] has been very good for our patients and our patient care that we provide.

The things we’ve succeeded in, are simply those— making sure that we have access to our patients, making sure that we keep them out of the hospital and the [emergency department] and have done really well in those areas and have shown improvement over time in those areas for patient care.

We’ve done some very simple things for drug utilization— drugs are a big cost of cancer care– and we’ve done some very simple things for managing drugs and drug utilization, for example using pathways and looking at other drugs like antiemetics and growth factors and making sure we’re using those appropriately.

What were challenged with right now is that next step, that next hurdle where things get a little bit more complicated. I’ve feel like we’ve done the easy things and the things that are easy to rally around and do well with for the practice, but now we’ve got to start making some very tough decisions to make that next hurdle and really succeed in the program.

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.